Feed MURA
MU

Mural Oncology plc MURA · NASDAQ

$2.04 +0.00% (+$0.00)

Summary

32 / 100 · Bulios Score

What speaks for it

  • It could repay all its net debt from 0.5 years of operating profit.

What to watch

  • The company made a loss over the last 12 months.
  • It passes only 2 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

There is not enough revenue history yet to say how fast it grows.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

No balance sheet is available.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

50% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

This revenue breakdown is on the way.

By region

This revenue breakdown is on the way.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.